Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus
Year: 2019
Type: article
Study design: Clinical Trial
Abstract: In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciy982
Authors: Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Srirompotong, Chaiwat Putiyanun, Tim R Cressey, Luc Decker, Woottichai Khamduang, Linda Harrison, Camlin Tierney, John A Shepherd, Athena P Kourtis, Marc Bulterys, George K Siberry, Gonzague Jourdain
Institutions: Institut de Recherche pour le Développement, Chiang Mai University, University of California, San Francisco, Maharaj Nakorn Chiang Mai Hospital, Harvard University, Nopparat Rajathanee Hospital, Samut Prakan Hospital, Nakornping Hospital, Khon Kaen Hospital, Chiang Kham Hospital, University of Liverpool, University of Hawaii Cancer Center, Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1256206920, G7543494365
OpenAlex ID: W2934042249